Home Companies Catalysts Deep Dives
Glovadalen UCB0022 PHASE2
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaNeurology
Peak Sales Est$1500M
Formulations[]
Companies
UCB (ORIGINATOR)100%
Mechanism: Dopamine D1 receptor PAM
Expert: Positive allosteric modulator of dopamine D1 receptors
Everyday: Positive allosteric modulator of dopamine D1 receptors
Targets: ["DRD1"]
Programs (1)
IndicationStageKey StudyRegional Status
Parkinson's diseasePHASE2Phase 2a[]
Data from Supabase · Updated 2026-03-24